Detalles de la búsqueda
1.
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Lancet
; 399(10336): 1695-1707, 2022 04 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-35405085
2.
Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: The CABIR study.
Int J Cancer
; 151(8): 1335-1344, 2022 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35603906
3.
Long survival of patients with metastatic clear cell renal cell carcinoma. Results of real life study of 344 patients.
Int J Cancer
; 146(6): 1643-1651, 2020 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31318983
4.
Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
Lancet Oncol
; 17(6): 747-756, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-27160475
5.
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 14(2): 149-58, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23306100
6.
Long-term Outcomes and Patterns of Relapse Following High-dose Elective Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Nodes in Prostate Cancer: OLIGOPELVIS (GETUG-P07).
Eur Urol
; 2024 Mar 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38490854
7.
Cost-effectiveness of weekly adaptive radiotherapy versus standard IMRT in head and neck cancer alongside the ARTIX trial.
Radiother Oncol
; 193: 110116, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38316193
8.
A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA.
Eur Urol
; 85(3): 274-282, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-37271630
9.
Weekly Adaptive Radiotherapy vs Standard Intensity-Modulated Radiotherapy for Improving Salivary Function in Patients With Head and Neck Cancer: A Phase 3 Randomized Clinical Trial.
JAMA Oncol
; 9(8): 1056-1064, 2023 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37261806
10.
Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol.
Clin Transl Radiat Oncol
; 40: 100613, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36968576
11.
Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial.
JAMA Oncol
; 9(12): 1629-1638, 2023 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37883073
12.
OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer.
Eur Urol
; 80(4): 405-414, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34247896
13.
Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database.
Eur J Cancer
; 125: 153-163, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31787484
14.
Early Toxicity of a Phase 2 Trial of Combined Salvage Radiation Therapy and Hormone Therapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (OLIGOPELVIS GETUG P07).
Int J Radiat Oncol Biol Phys
; 103(5): 1061-1067, 2019 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30557672
15.
Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer.
Eur J Cancer
; 97: 41-48, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29636272
16.
Induction Chemotherapy Followed by Cetuximab Radiotherapy Is Not Superior to Concurrent Chemoradiotherapy for Head and Neck Carcinomas: Results of the GORTEC 2007-02 Phase III Randomized Trial.
J Clin Oncol
; 36(31): 3077-3083, 2018 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30016178
17.
Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial.
J Clin Oncol
; : JCO2017762518, 2018 Jun 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29878867
18.
Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database.
Eur Urol Oncol
; 1(6): 467-475, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31158090
19.
Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Eur Urol
; 73(5): 696-703, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29074061
20.
[French national survey on incoming phone calls in oncology departments]. / Enquête nationale française sur les appels téléphoniques entrants en oncologie médicale.
Bull Cancer
; 104(6): 565-573, 2017 Jun.
Artículo
en Francés
| MEDLINE | ID: mdl-28391984